Across TCGA pan-cancer cohorts, LINC02817 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC02817 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LINC02817 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02817 expression acts as an unfavorable survival marker.
UCEC and CHOL are the cancer types where LINC02817 Mutation most reproducibly stratifies survival.